Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Progress for radiology drugs and medical imaging company

Voyageur Pharmaceuticals ( TSXV:VM ) ( OTC:VYYRF ) is focused on vertically integrating the barium, iodine and carbon contrast imaging market – think radiology drugs and medical imaging. Its business plan is set to generate immediate cash flow by partnering with thir...
Shoran Devi | June 12, 2023 |

A ‘Novel’ Investment In Psychedelic-Inspired Medicines

Stockhouse investors are keenly aware of the booming trend in the psychedelic healthcare space…in many ways the new Cannabis 2.0 over the last 12 – 24 months. Capital markets have taken to them en masse – a market now estimated to be in excess of USD$5 billion and expected ...
Dave Jackson | April 16, 2021 |

Developer of Cannabinoid-Based Drugs to Resume Cancer Pain Trial

Calling this latest development "excellent news," Paradigm Capital has raised its target price on the company's stock. In an April 9 research note, analyst Rahul Sarugaser reported that Paradigm Capital raised its target price on Tetra Bio-Pharma Inc. (TBP:TSX.V; TBPMF...
Streetwise Reports | April 18, 2019 |

This Medical Device Company Plans to Grow its Business Through M&A

(Click image to watch video) North America is one of the hottest spots for the medical device industry, having accounted for nearly half of all market revenue in 2019. According to a report , medical devices continue to rise in importance for disease preventio...
Jocelyn Aspa | June 10, 2021 |

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Could DehydraTECH CBD be Worth $3 Billion a Year to Lexaria?

PCG Digital -- Hypertension, or high blood pressure as it's commonly known, affects over three million Americans every year and is a primary or contributing cause of death for 25% of them. On a global scale, hypertension kills roughly 7.6 milli on people per year . L...
Featured Submission | March 9, 2021 |

Why is this Company combining Artificial Intelligence and Psychedelics to address Mental Afflictions

(Click image to play video) Did you know that in Canada, it is estimated that by the age of 40, half of the population will have, or will have had, a mental illness? The recent surge of interest in psychedelic drugs is due to their potential for more effective tr...
Dave Jackson | May 10, 2021 |

Buzz on the Bullboards: Whose stocks sizzle during summer holidays?

As we get through the summer holiday season, the typically calmer market environment presents a prime opportunity for investors to evaluate their portfolios and consider new investments. The TSX continues to offer a variety of promising stocks, particularly in energ...
Jonathon Brown | July 4, 2024 |

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

Valeo Pharma Big Pharma Capabilities Presents Opportunity

Valeo Pharma Inc. is a Canadian specialty pharmaceutical company with big pharma capabilities while retaining small company flexibilities. Valeo is a fast-growing revenue generating company with a strong product portfolio and a robust product pipeline. Valeo Pharma In...
Fredrick William | May 15, 2020 |
1 2 3 4 5 6 7 8 9 10 ...